DRTS is technically overbought after a strong run that has already reached its V8 price target, compounded by a four-quarter earnings miss streak and modest insider selling, leaving negative risk/reward asymmetry.
Thesis pillars
- Overbought Momentum Run↓Deteriorating
- Four Quarter Earnings Miss Streak↓Deteriorating
- Negative Risk Reward Asymmetry↑Improving
- +1 more pillar — see the Why tab for full reasoning
Alpha Tau Medical Ltd. (DRTS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $14.68: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for... Read more
Sell if holding. Engine safety override at $14.68: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 43 mid-range, Bollinger mid-band. Score 4.5/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 68d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-09-13Recent Developments — Alpha Tau Medical Ltd.
Latest news
- NEWS Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30 — benzinga Sep 3, 2026 positive
- NEWS Alpha Tau Medical Announces Completion Of Enrollment Of 48 Patients In Phase Pilot IMPACT Study Of Alpha DaRT With First — benzinga Aug 31, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16 — benzinga Aug 11, 2026 positive
- NEWS Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate — benzinga Aug 10, 2026 negative
- NEWS HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target — benzinga Jul 22, 2026 positive
Generated 2026-09-14T05:21:57Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.68: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 43 mid-range, Bollinger mid-band. Prior stop was $13.42. Score 4.5/10, moderate confidence.
Take-profit target: $15.49 (+7.3% upside). Prior stop was $13.42. Stop-loss: $13.42.
Quality below floor (1.5 < 4.0).
Alpha Tau Medical Ltd. trades at a P/E of N/A (forward -27.0). TrendMatrix value score: 6.0/10. Verdict: Sell.
11 analysts cover DRTS with a consensus score of 4.2/5. Average price target: $18.
What does Alpha Tau Medical Ltd. do?Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and...
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.